Loading data for FDMT — first visit, this takes a few seconds.

Alerta

4D Molecular Therapeutics... (FDMT)

NasdaqGS: FDMT · Precio en tiempo real · USD

14.72

+0.18 (1.24%)

Al cierre: Aug 18, 2026, 3:59 PM

1.24% (1D)

Precio de compra	10.76
Capitalización de mercado	835.29M
Ingresos (TTM)	92.01M
Beneficio neto (TTM)	-179.18M
Beta	2.69
EPS (TTM)	-2.63
Ratio PER (TTM)	n/a
Adelante PE	-3.7
P/B (TTM)	2.05
P/S (TTM)	9.08
Earnings Date	Nov 10, 2026

Precio de venta	17.94
Volumen	1,602,245
Volumen medio (20D)	909,940
Abierto	14.25
Anterior Cerrar	14.54
Rango del día	13.91 - 15.04
Rango de 52 semanas	5.97 - 15.04
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de FDMT

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injec...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Dec 11, 2020

Empleados 196

Bolsa de Valores NasdaqGS

Símbolo bursátil FDMT

Sitio web https://www.4dmoleculartherapeutics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de 4D Molecular Therapeutics fueron 85.21M, un aumento de 230,194.59% en comparación con 37K del año anterior. Las ganancias fueron -140.11M, una disminución de -12.9%.

Estados financieros

Sorpresa de resultados

4D Molecular Therapeutics ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $3.05M falla las estimaciones por $0, con 21664.29% Crecimiento interanual.

EPS de -1.04 falla las estimaciones por -0.02, con -6.12% Disminución interanual.

Próxima publicación de resultados

Está previsto que 4D Molecular Therapeutics Inc. publique sus resultados el Nov 10, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 día hace · Stocktwits

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

5 días hace · Zacks

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

6 días hace · Zacks

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 semana hace · Zacks

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

2 semanas hace · Zacks

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Página 1 de 2